At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Alisertib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
In Brief
A Phase 2 clinical trial evaluating Alisertib and Laboratory Biomarker Analysis for Recurrent Uterine Corpus Sarcoma and Uterine Corpus Leiomyosarcoma. Completed, enrolled 23 participants across 50 sites.
Detailed Summary
This phase II trial studies how well alisertib works in treating patients with leiomyosarcoma of the uterus that has come back or persistent. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNRG Oncology
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartAug 2012
Primary CompletionAug 2014
Study CompletionFeb 2017
TodayJul 2026
First PostedJul 11, 2012
Enrollment StartAug 1, 2012
Primary CompletionAug 1, 2014
Study CompletionFeb 11, 2017
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.0 years ago
Interventions
Alisertibdrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies